BBIO Stock Analysis: Buy, Sell, or Hold?
BBIO - BridgeBio Pharma, Inc. Common Stock
$84.48
1.68 (2.03%)
â˛
5d:
+5.48%
30d:
-6.31%
90d:
+25.25%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When BBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BBIO is fairly priced but lacks strong directional signals. At -9.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BBIO is fairly priced but lacks strong directional signals. At -9.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.32
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$12.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BBIO is currently trading at $84.48, which is considered slightly high relative to its 30-day fair value range of $77.62 to $85.09. From a valuation perspective, the stock is trading at a discount (Forward PE: 145.6) compared to its historical average (194.1). Remarkably, the market is currently pricing in an annual earnings decline of 9.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BBIO is in a strong uptrend. The price is approaching resistance at $86.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (49/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $106.19 (+25.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBIO is in a strong uptrend. The price is approaching resistance at $86.32. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (49/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $106.19 (+25.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$77.62 -
$85.09
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
Protect Your Profits
Holding BBIO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (49/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($106.19)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$77.62 -
$85.09
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$78.82
Resistance Level
$86.32
Current Trend
Strong Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
145.60
Wall Street Target
$106.19
(+25.7%)
Revenue Growth (YoY)
66.8%
Profit Margin
-124.4%
Valuation Discount vs History
-9.1% cheaper
PE vs Historical
145.6 vs 194.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.1%
(market-implied from PE analysis)
1-Year Target
$76.79
(-9%)
2-Year Target
$69.80
(-17%)
3-Year Target
$63.45
(-25%)
3-Yr Target (if PE normalizes)
(PE: 146â194)
$84.59
(+0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 145.6 to 194.1
Stabilization Target:
$112.62
(+33.3%)
PE Expansion Potential:
+33.3%
Share & Embed Analysis
Last updated: August 08, 2026 4:54 PM ET
Data refreshes hourly during market hours. Next update: 5:54 PM
Data refreshes hourly during market hours. Next update: 5:54 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBIO showing a specific setup today?
Insider Activity (6 Months)
3
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Neil Kumar
SELL
40000 shares
2026-04-09
Gilbert Ray Cisneros, Jr.
BUY
2026-03-19
Gilbert Ray Cisneros, Jr.
BUY
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$386 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$557 | 43 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 44 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 63 BUY |
Advanced BBIO Option Strategies
Professional options setups generated by AI based on today's BBIO price and gamma walls.
